Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.

Noriaki Kawano, Nobuyuki Ono, Shuro Yoshida, Takuro Kuriyama, Kiyoshi Yamashita, Kiichiro Beppu, Yoshiya Shimao, Kosuke Marutsuka, Yuji Ueda, Akira Ueda

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    Immunodeficiency-associated lymphoproliferative disorders (LPD) in rheumatoid arthritis are a rare, aggressive, and life-threatening clinical entity. We describe a 60-year-old man who had rheumatoid arthritis that was treated with methotrexate. Eight months after the treatment, the case was diagnosed as Epstein-Barr virus-negative LPD (diffuse large B-cell lymphoma) with abdominal bulky mass and clinical stage IVB at high risk in the international prognostic index. Immediate withdrawal of methotrexate led the patient to achieve complete remission, and 8 subsequent courses of rituximab treatment for the prevention of relapse kept the patient disease-free for 29 months. Our case suggests that these treatments may be an effective, safe, and feasible strategy for immunodeficiency-associated LPD in rheumatoid arthritis.

    Original languageEnglish
    Pages (from-to)193-198
    Number of pages6
    JournalJournal of clinical and experimental hematopathology : JCEH
    Volume52
    Issue number3
    DOIs
    Publication statusPublished - 2012

    All Science Journal Classification (ASJC) codes

    • Medicine(all)

    Fingerprint Dive into the research topics of 'Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.'. Together they form a unique fingerprint.

    Cite this